Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection.

Batteson, Rachael; Hart, Rose; Hemstock, Matthew; Gooden, Kyna; Kotapati, Srividya; Roze, Stephane; Lee, Dawn; Amadi, Adenike

Batteson, Rachael; Hart, Rose; Hemstock, Matthew; Gooden, Kyna; Kotapati, Srividya; Roze, Stephane; Lee, Dawn; Amadi, Adenike.

Afiliación

Batteson R; BresMed, Steel City House, West Street, Sheffield, S1 2GQ, UK. rbatteson@bresmed.com.
Hart R; BresMed, Steel City House, West Street, Sheffield, S1 2GQ, UK.
Hemstock M; BresMed, Steel City House, West Street, Sheffield, S1 2GQ, UK.
Gooden K; Bristol-Myers Squibb, Princeton, NJ, USA.
Kotapati S; Bristol-Myers Squibb, Princeton, NJ, USA.
Roze S; HEVA HEOR, Lyon, France.
Lee D; BresMed, Steel City House, West Street, Sheffield, S1 2GQ, UK.
Amadi A; Bristol-Myers Squibb, Uxbridge, UK.

Pharmacoecon Open ; 4(2): 343-351, 2020 Jun.

Article en En | MEDLINE | ID: mdl-31587138

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Pharmacoecon Open Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google